Acquisitions, Investments, and Licenses - Summary of Pro Forma Results (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2015 |
Dec. 31, 2014 |
|
| EirGen Pharma Limited | ||
| Business Acquisition [Line Items] | ||
| Revenues | $ 495,993 | $ 105,973 |
| Net loss | (32,481) | (176,563) |
| Net loss attributable to common shareholders | (31,081) | (173,590) |
| Bio-Reference Laboratories, Inc. | ||
| Business Acquisition [Line Items] | ||
| Revenues | 1,052,462 | 923,407 |
| Net loss | (19,456) | (140,854) |
| Net loss attributable to common shareholders | $ (18,055) | $ (137,881) |
| X | ||||||||||
- Definition Business Acquisition, Pro Forma Net Income (Loss) Available to Common Stockholders No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|